Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) Nuclear Science and Technology (3)
- Advanced Manufacturing (1)
- Biology and Environment (9)
- Clean Energy (17)
- Computational Engineering (1)
- Fusion and Fission (9)
- Fusion Energy (3)
- Isotopes (1)
- Materials (22)
- Materials for Computing (1)
- National Security (8)
- Neutron Science (12)
- Supercomputing (16)
News Topics
- (-) Biomedical (1)
- (-) Fusion (1)
- (-) Physics (1)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (2)
- Bioenergy (1)
- Computer Science (1)
- Decarbonization (1)
- Isotopes (2)
- Materials Science (1)
- Neutron Science (1)
- Nuclear Energy (7)
- Space Exploration (2)
- Sustainable Energy (1)
- Transformational Challenge Reactor (1)
Media Contacts
Juergen Rapp, a distinguished R&D staff scientist in ORNL’s Fusion Energy Division in the Nuclear Science and Engineering Directorate, has been named a fellow of the American Nuclear Society
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
After more than a year of operation at the Department of Energy’s (DOE’s) Oak Ridge National Laboratory (ORNL), the COHERENT experiment, using the world’s smallest neutrino detector, has found a big fingerprint of the elusive, electrically neutral particles that interact only weakly with matter.